Destination therapy: An alternative for end-stage heart failure patients not eligible for heart transplantation

Current Opinion in Organ Transplantation

Volumn 10, Issue 4, 2005, Pages 369-375

  Cadeiras, Martin ^a   Von Bayern, Manuel Prinz ^a   Pal, Amandeep ^a   Asai, Tomohiro ^a   Naka, Yoshifumi ^a   Deng, Mario C ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Advanced heart failure; Destination therapy; Mechanical circulatory support device; Risk evaluation

Indexed keywords

AGE DISTRIBUTION; BLOOD CLOTTING DISORDER; HEART ARRHYTHMIA; HEART FAILURE; HEART TRANSPLANTATION; HIGH THROUGHPUT SCREENING; HUMAN; INFECTION; KIDNEY FAILURE; PRACTICE GUIDELINE; PREDICTION; REVIEW; SURVIVAL;

EID: 28044444275     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000187101.11157.1c     Document Type: Review

References (58)

1. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-551.
2. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237.
3. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539-1549.
4. Crespo Leiro MG, Paniagua Martin MJ. Management of advanced or refractory heart failure. Rev Esp Cardiol 2004; 57:869-883.
5. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365:1877-1889.
6. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:384-416.
7. Jimenez J, Bennett Edwards L, Higgins R, et al. Should stable UNOS status 2 patients be transplanted? J Heart Lung Transplant 2005; 24:178-183. This article confirms prior observations on the absence of survival benefit from heart transplantation compared with waiting list mortality at 1 year for patients listed under the United Network for Organ Sharing 2 waiting list status.
8. Morris RJ, Pochettino A, O'Hara M, et al. Emergent mechanical support in the community: improvement with early transplant center referral. J Heart Lung Transplant 2005; 24:764-768.
9. Digiorgi PL, Reel MS, Thornton B, et al. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant 2005; 24:200-204.
10. Grady KL, Meyer PM, Dressler D, et al. Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation. Ann Thorac Surg 2004; 77:1321-1327.
11. Bramstedt KA, Nash PJ. When death is the outcome of informed refusal: dilemma of rejecting ventricular assist device therapy. J Heart Lung Transplant 2005; 24:229-230.
12. Hauptman PJ, Havranek EP. Integrating palliative care into heart failure care. Arch Intern Med 2005; 165:374-378.
13. Deng MC, Edwards LB, Taylor DO, et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report 2005. J Heart Lung Transplant 2005; 24:1182-1187. The annual report of the ISHLT Mechanical Support Database serves as a continuous repository of data on indication, complications, and survival of patients undergoing MCSD. Detailed explanatory slide sets are available at http://www.ishlt. org/registries/slides.asp?slides=mcsd.
14. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345:1435-1443.
15. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 2005; 129:9-17. This outcome analysis shows an improvement in survival and QoL for patients who were enrolled during the second half of the REMATCH trial compared with the first half and confirms benefit of MCSD over optimal medical management after 2 years.
16. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004; 110:975-981. The use of inotropes in AHF had been classically linked to a worst survival. This subanalysis of the REMATCH trial showed that this observation might not apply to MCSD patients and that survival benefit might be seen only in patients predicted to have a 1-year survival rate lower than 50% at the time of evaluation.
17. Stevenson LW. Left ventricular assist devices as destination therapy for end-stage heart failure. Curr Treat Options Cardiovasc Med 2004; 6:471-479.
18. Young JB, Rogers JG, Portner PM et al. Bridge to eligibility: LVAS-support in patients with relative contraindications to transplantation. J Heart Lung Transplant 2005; 24:S75.
19. Jurmann MJ, Weng Y, Drews T, et al. Permanent mechanical circulatory support in patients of advanced age. Eur J Cardiothorac Surg 2004; 25:610-618.
20. Siegenthaler MP, Westaby S, Frazier OH, et al. Advanced heart failure: study feasibility of long term continuous axial flow pump support. Eur Heart J 2005; 26:1031-1038.
21. Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis 2005; 40:1108-1115. This experience reflects the major challenge of infections in MCSD candidates in a bridge-to-transplantation population, risk factors, potential complications, and algorithms used for prevention and treatment of infections related to MCSD.
22. Holman WL, Park SJ, Long JW, et al. Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant 2004; 23:1359-1365. This paper focuses on occurrence of infectious complications including sepsis and drive line, pocket, pump housing, inflow or outflow tract infections; impact on survival; and protocols and algorithms for prevention and treatment of infections followed during the REMATCH trial.
23. Lazar RM, Shapiro PA, Jaski BE, et al. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation 2004; 109:2423-2427. This REMATCH substudy analyzed cerebrovascular, metabolic, and other neurologic events in patients with left ventricular assist devices and those receiving optimal medical treatment and the impact of these events on survival.
24. Guthikonda S, Lev EI, Kleiman NS. Resistance to antiplatelet therapy. Curr Cardiol Rep 2005; 7:242-248.
25. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285-2293.
26. Salzberg SP, Lachat ML, von Harbou K, et al. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg 2005; 27:222-225.
27. Martin J, Siegenthaler MP, Friesewinkel O, et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation: a preliminary study. Eur J Cardiothorac Surg 2004; 25:971-977.
28. Ziv O, Dizon J, Thosani A, et al. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol 2005; 45:1428-1434.
29. Dowling RD, Park SJ, Pagani FD, et al. HeartMate VE LVAS design enhancements and its impact on device reliability. Eur J Cardiothorac Surg 2004; 25:958-963.
30. Birks EJ, Tansley PD, Yacoub MH, et al. Incidence and clinical management of life-threatening left ventricular assist device failure. J Heart Lung Transplant 2004; 23:964-969.
31. Horton SC, Khodaverdian R, Chatelain P, et al. Left ventricular assist device malfunction: an approach to diagnosis by echocardiography. J Am Coll Cardiol 2005; 45:1435-1440.
32. Horton SC, Khodaverdian R, Powers A, et al. Left ventricular assist device malfunction: a systematic approach to diagnosis. J Am Coll Cardiol 2005; 43:1574-1583.
33. Gwechenberger M, Hülsmann M, Berger R, et al. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant 2004; 23:839-844.
34. Houel R, Mazoyer E, Boval B, et al. Platelet activation and aggregation profile in prolonged external ventricular support. J Thorac Cardiovasc Surg 2004; 128:197-202.
35. Toumpoulis IK, Anagnostopoulos CE, Swistel DG, DeRose JJ Jr. Does EuroSCORE predict length of stay and specific postoperative complications after cardiac surgery? Eur J Cardiothorac Surg 2005; 27:128-133.
36. Rodrigue-Way A, Burkhoff D, Geesaman BJ, et al. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant 2005; 24:73-80.
37. Rao V, Oz MC, Flannery MA, et al. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc Surg 2003; 125:855-862.
38. Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant 2004; 23:1414-1422. The HFSS was validated for risk estimation of heart failure patients and prediction of survival after heart transplantation before the β-blocker era. This new study suggests that the HFSS can still be a reliable tool for risk evaluation in this population.
39. Schonhofer B, Guo JJ, Suchi S, et al. The use of APACHE II prognostic system in difficult-to-wean patients after long-term mechanical ventilation. Eur J Anaesthesiol 2004; 21:558-565.
40. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336-343.
41. Ruf AE, Villamil FG. Which is the holy grail in liver transplantation: hyponatremia, MELD, or a combination? Liver Transpl 2005; 11:711.
42. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41:26-31.
43. Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005; 16:162-168.
44. Nguyen MT, Ross GF, Dent CL, Devarajan P. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 2005; 25:318-326.
45. Ostermann ME,Chang RW. Riyadh ICU Program Users Group. Prognosis of acute renal failure: an evaluation of proposed consensus criteria. Intensive Care Med 2005; 31:250-256.
46. Basso K, Margolin A, Stolovitzky G, et al. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37:382-390.
47. O'Neill AJ, Doyle BT, Molloy E, et al. Gene expression profile of inflammatory neutrophils: alterations in the inhibitors of apoptosis proteins during spontaneous and delayed apoptosis. Shock 2004; 21:51-58.
48. Deng MC, Eisen HJ, Mehra RM, et al. Non-invasive detection of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2005; in press.
49. Consales G, De Gaudio AR. Sepsis associated encephalopathy. Minerva Anestesiol 2005; 71:39-52.
50. Liaw PC, Esmon CT, Kahnamoui K, et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104:3958-3964.
51. Pachot A, Monneret G, Brion A, et al. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 2005; 33:31-38.
52. Texereau J, Pene F, Chiche JD, et al. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32S:313-319.
53. D'Aiuto F, Casas JP, Shah T, et al. C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 2005; 179:413-417.
54. Wang JE. Can single nucleotide polymorphisms in innate immune receptors predict development of septic complications in intensive care unit patients? Crit Care Med 2005; 33:695-696.
55. Sharma UC, Pokharel S, Evelo CT, Maessen JG. A systematic review of large scale and heterogeneous gene array data in heart failure. J Mol Cell Cardiol 2005; 38:425-432.
56. Olman MA, White KE, Ware LB, et al. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J Immunol 2004; 172:2668-2677.
57. Prucha M, Ruryk A, Boriss H, et al. Expression profiling: toward an application in sepsis diagnostics. Shock 2004; 22:29-33.
58. Henger A, Kretzler M, Doran P. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 2004; 65:904-917.